.jpg)
2 hours ago
4
Article content
Funding to advance MindRank’s AI-native drug R&D engine and innovative pipeline, including MDR-001, an oral small-molecule GLP-1 receptor agonist in Phase III clinical development in China
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
HANGZHOU, China, July 09, 2026 (GLOBE NEWSWIRE) — MindRank AI Ltd. (“MindRank”), a clinical-stage biotechnology company dedicated to building an AI-native engine for drug research and development, today announced the completion of a $52 million Series B financing. The round was led by a group of institutional and healthcare funds.
Article content
Article content
Article content
MindRank was founded with the ambition of reimagining how innovative medicines are discovered and developed. Its proprietary Molecule Arts Platform (MAP) integrates biology, chemistry, computation, experimental evidence and clinical learning into a unified R&D system designed to support the discovery and development of new medicines.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
The financing will support the continued advancement of MAP, as well as the progression of MindRank’s clinical and preclinical pipeline. The company’s lead program, MDR-001, is an oral small-molecule GLP-1 receptor agonist currently in Phase III clinical development in China. The program entered Phase III in 2025 and advanced from project initiation to Phase III in approximately 4.5 years. Cumulative R&D investment from project initiation through the start of Phase III in China has been approximately US$23 million.
Article content
Beyond MDR-001, MindRank has obtained 3 IND clearances in China and the United States and has nominated 5 additional preclinical development candidates. Together, these programs demonstrate the capability of MAP across multiple stages of drug discovery and development.
Article content
Article content
“Our goal is to translate advances in computation and artificial intelligence into better medicines for patients,” said Zhangming Niu, Founder and Chief Executive Officer of MindRank. “By integrating biological, chemical, computational and clinical data into a continuously learning R&D engine, MAP is designed to make drug discovery and development more predictable, scalable and capital-efficient.”
Article content
About MindRank
Article content
MindRank is a clinical-stage AI-native biotechnology company developing an end-to-end platform for pharmaceutical research and development. Its proprietary Molecule Arts Platform (MAP) combines multi-agent AI systems, generative molecular design, computational biology, experimental validation and clinical learning within a unified drug discovery platform. By integrating AI across the entire R&D workflow, MindRank aims to make the discovery and development of innovative medicines faster, more scalable and more predictable.
Article content
For more information, visit www.mindrank.ai.
For BD inquiries, contact [email protected].
For PR inquiries, contact [email protected].
Article content
Article content
Article content
Article content
Article content
Article content
English (US)